Efficacy And Safety Assessment Of DEB-TACE And CTACE For The Treatment Of Unresectable Hepatocellular Carcinoma

Purpose:This study aimed at performing a retrospective comparing DEB-TACE and cTACE in the treatment of unresectable hepatocellular carcinoma and observing efficacy and adverse effects.Methods:We retrospectively analyzed 40 unresectable hepatocellular carcinoma patients from June 2016 to May 2017 at The Second Affiliated hospital of Nanchang University,of which 20 cases treated with DEB-TACE as treatment group,20 cases of patients with cTACE as control group.Following-up these patients every months,using the latest evaluation criteria for the efficacy of solid tumors mRECIST to evaluate efficacy.The objective response rate(ORR),disease control rate(DCR)and time to progression(TTP)were evaluated using SPSS17.0.Log-rank test was used for single factor analysis,and p<0.05 indicated that the difference was statistically significant.Meanwhile,the COX proportional hazards model was applied for multivariate analysis of prognostic factors.Results:1?There were no statistically significant differences in any of the baseline characteristics.The median TTP in DEB-TACE group and cTACE group were 8.0(95% CI 6.5–9.5)months and 6.0(95% CI 3.4–8.6)months respectively,p =0.09,the difference was significant.Multivariate analysis showed that the treatment method,tumor diameter and AFP value were independent prognostic factors of TTP.2? The short-term effect of treatment group and control group showed that 1 months ORR was 80% VS 60%,DCR was 95% VS 90%;3 months ORR was 60% VS 55%,DCR was 85% VS 80%;6 months ORR was 40% VS 30%,DCR was 80% VS 70%.There were no cases of death due to transcatheter arterial chemoe mbolization in both the treatment group and the control group.The was no significant difference in the adverse reaction between the two groups,such as abdominal pain,fever,nausea and fatigue(p>0.05).Conclusions:1?It is safe and feasible for patients with unresectable hepatocellular carcinoma to treated with DEB-TACE and cTACE.There were no significant differences between DEB-TACE and cTACE with regard to the short-term effects.2?DEB-TACE compared with cTACE treatment for unresectable hepatocellular carcinoma can improve the patient's TTP.The short term effect of the unresectable hepatocellular carcinoma patients could not be significantly improved.